Senator Urges Consensus on Tobacco Law

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 7 No 2
Volume 7
Issue 2

WASHINGTON-Amid political bickering on Capitol Hill over the proposed tobacco settlement and the gloomy prediction of Senate Majority Leader Trent Lott (R-Miss) that legislation needed to implement the pact stands only a 30% chance of passage, a powerful Senate chairman gently warned public health groups that discord within their own ranks isn’t helping the situation.

WASHINGTON—Amid political bickering on Capitol Hill over the proposed tobacco settlement and the gloomy prediction of Senate Majority Leader Trent Lott (R-Miss) that legislation needed to implement the pact stands only a 30% chance of passage, a powerful Senate chairman gently warned public health groups that discord within their own ranks isn’t helping the situation.

In a letter to 34 organizations, including the American Medical Association and the American Cancer Society, Sen. John McCain (R-Ariz) urged the groups “to develop a consensus, where possible, concerning the key components of comprehensive tobacco legislation.”

Sen. McCain chairs the Committee on Commerce, Science, and Transportation, which will hold a series of hearings on the settlement proposal and play a major role in writing any tobacco law.

“The importance of a public health coalition reaching a common position on the details of the settlement cannot be overstated,” he said. “Legislative progress would be seriously impeded if the public health community is not fully engaged and substantially in accord.”

Sen. McCain said that Congress must address “extremely complex issues related to the tobacco settlement and national tobacco policy” and that consensus will be critical to drafting legislation that will win the support of the public, Congress, and the Clinton Administration.

“Clearly, the public health community must play a vital role in the process if we are to craft an appropriate legislative approach,” he said.

Recent Videos
Future findings from a translational analysis of the OVATION-2 trial may corroborate prior clinical data with IMNN-001 in advanced ovarian cancer.
The dual high-affinity binding observed with ISB 2001 may avoid resistance mechanisms reported with other BCMA-targeted therapies.
The use of chemotherapy trended towards improved recurrence-free intervals in older patients with high-risk tumors as determined via the MammaPrint assay.
Use of a pharmacist-directed resource appears to improve provider confidence and adverse effect monitoring for patients undergoing infusion therapy.
Reshma L. Mahtani, DO, describes how updates from the DESTINY-Breast09, ASCENT-04, and VERITAC-2 trials may shift practices in the breast cancer field.
Related Content